ClinicalTrials.gg
TerminatedNCT00655668EXPECTUpdated Nov 25, 2019Results posted

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

A Phase 2 interventional study of Lenalidomide in T-cell Non-Hodgkin's Lymphoma, sponsored by Celgene. Terminated at 45 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was terminated
Decision not to pursue as single agent in the study population.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing lenalidomide in Lymphoma, T-Cell — none open to participants now, none under way, none of them phase 3. Lenalidomide · Lymphoma, T-Cell.

Enrollment
5th of 13
54 · median 41
Started
2008
with 1 other
Phase 2
6 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
1 of 13
Celgene

Among the 13 studies testing lenalidomide in Lymphoma, T-Cell, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 2, and was the 2nd registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

None of the 13 studies testing lenalidomide in Lymphoma, T-Cell is open now. The open studies under Lymphoma, T-Cell, anywhere →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Lymphoma, T-Cell studies recruiting now, 41 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing lenalidomide in Lymphoma, T-Cell as a file.
02

Study summary

This is a Phase II, multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to subjects with relapsed or refractory T-cell lymphoma. This study will be conducted in two phases: a Treatment Phase and a Follow-up Phase.

Subjects who qualify for enrollment into the study will enter the Treatment Phase and receive single-agent lenalidomide 25 mg once daily on Days 1-21 every 28 days (28-day cycles). Subjects may continue participation in the Treatment Phase of the study for a maximum duration of 24 months, or until disease progression or unacceptable adverse events develop.

All subjects who discontinue the Treatment Phase for any reason will continue to be followed until progression of disease or until next lymphoma treatment is given, whichever comes first, during the Follow-up Phase.

Objectives:

Primary:

  • To determine the efficacy of lenalidomide monotherapy in relapsed or refractory T-cell Non-Hodgkin's Lymphoma (NHL). Efficacy will be assessed by measuring the response rate, tumor control rate, duration of response, time to progression and progression free survival.

Secondary:

  • To evaluate the safety of lenalidomide monotherapy as treatment for subjects with relapsed or refractory T-cell NHL.
Read the detailed description

Study was terminated. Study data assessment revealed that study drug is active, but is not likely to be sufficiently active as a single agent in this population for registration purposes.

03

Conditions studied

  • T-cell Non-Hodgkin's Lymphoma

Keywords

  • NHL, Non-Hodgkin's Lymphoma, T-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must understand and voluntarily sign an form.
  • Must be ≥ 18 years of age at the time of signing the informed consent form.
  • Must be able to adhere to the study visit schedule and other protocol requirements.
  • -proven T-cell Non-Hodgkin's Lymphoma, either:

    • Peripheral T-cell Lymphoma (PTCL) whatever the subtype, or
    • Cutaneous T-cell Lymphoma (CTCL), but only the subtype mycosis fungoides.
  • to previous therapy for T-cell Non-Hodgkin's Lymphoma.
  • Must have received at least one prior combination chemotherapy regimen. There is no limit on the number of prior therapies.

Exclusion criteria

Exclusion Criteria:

  • Cutaneous T-cell Lymphoma of subtype Sézary Syndrome.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Lenalidomide

    Open-label, oral lenalidomide monotherapy

    Drug: Lenalidomide

Interventions

  • Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle

    Also known as: Revlimid

06

What researchers measure

Primary outcomes

  1. Participants Categorized by Best Response as Determined by Investigator

    Participant response assessed by investigator; criteria by B. Cheson in Journal of Clinical Oncology, 1999 (see article for more detail): * Complete Response(CR): Complete disappearance of all detectable disease * Complete Response Unconfirmed(CRu): CR, but indeterminate bone marrow * Partial Response(PR): \>50% decrease in six largest nodes/nodal masses * Stable Disease(SD): Less than PR, but not progressive disease * Relapsed Disease: In CR/CRu Patients, new lesions seen or increased by \>=50% in previous sites * Progressive Disease(PD): \>=50% increase from low in PR/Non-Responders

    Time frame: Up to 24 months

Secondary outcomes

  1. Duration of Response

    Kaplan-Meier Estimate of duration of response calculated as the time from first computed tomography (CT) Scan or magnetic resonance imaging (MRI) that demonstrates at least a partial response to the first documentation of disease progression, including death due to Non-Hodgkin's Lymphoma.

    Time frame: Up to 24 months

  2. Time-to-Progression

    Kaplan-Meier estimate of time-to-progression is calculated as the time from the start of study drug therapy to the first documentation of progressive disease.

    Time frame: Up to 24 months

  3. Progression-Free Survival

    Kaplan-Meier estimate of progression-free survival is defined as the start of study drug therapy to the first observation of disease progression or death due to any cause.

    Time frame: Up to 24 months

  4. Safety

    Summary of Treatment-Emergent Events in Safety Population (participants with at least one dose of study drug). Events assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3: Following is the scale: Grade 1=Mild Adverse Event (AE), Grade 2=Moderate AE, Grade 3=Severe and Undesirable AE, Grade 4=Life-threatening or Disabling AE, and Grade 5=Death Related to AE.)

    Time frame: Up to 24 months

07

Results

Posted Jan 5, 2012

Participant flow

Recruiting began March 2008; first participant enrolled 16 June 2008 and last participant enrolled 29 January 2010.

Participant flow — Overall Study
MilestoneSingle Agent Lenalidomide
Started54
Completed0
Not completed54
Withdrew: Adverse event6
Withdrew: Death5
Withdrew: Disease progression27
Withdrew: Study terminated9
Withdrew: Other1
Withdrew: New lymphoma treatment started4
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryParticipants Categorized by Best Response as Determined by Investigator

Participant response assessed by investigator; criteria by B. Cheson in Journal of Clinical Oncology, 1999 (see article for more detail): * Complete Response(CR): Complete disappearance of all detectable disease * Complete Response Unconfirmed(CRu): CR, but indeterminate bone marrow * Partial Response(PR): \>50% decrease in six largest nodes/nodal masses * Stable Disease(SD): Less than PR, but not progressive disease * Relapsed Disease: In CR/CRu Patients, new lesions seen or increased by \>=50% in previous sites * Progressive Disease(PD): \>=50% increase from low in PR/Non-Responders

Time frame:
Up to 24 months
Reported as:
Number · Participants
Participants Categorized by Best Response as Determined by Investigator
ParticipantsSingle Agent Lenalidomide
Complete Response (CR)4
Complete Response Unconfirmed (CRu)2
Partial Response (PR)6
Stable Disease (SD)16
Progressive Disease (PD)16
No Response Assessment9
Other1
Tumor Control (CR+CRu+PR+SD)28
SecondaryDuration of Response

Kaplan-Meier Estimate of duration of response calculated as the time from first computed tomography (CT) Scan or magnetic resonance imaging (MRI) that demonstrates at least a partial response to the first documentation of disease progression, including death due to Non-Hodgkin's Lymphoma.

Time frame:
Up to 24 months
Reported as:
Median · Months
Duration of Response
MonthsSingle Agent Lenalidomide
Duration of Response3.55 (3.1562 to 7.6274)
SecondaryTime-to-Progression

Kaplan-Meier estimate of time-to-progression is calculated as the time from the start of study drug therapy to the first documentation of progressive disease.

Time frame:
Up to 24 months

No measurements were reported for this outcome.

SecondaryProgression-Free Survival

Kaplan-Meier estimate of progression-free survival is defined as the start of study drug therapy to the first observation of disease progression or death due to any cause.

Time frame:
Up to 24 months
Reported as:
Median · Months
Progression-Free Survival
MonthsSingle Agent Lenalidomide
Progression-Free Survival2.53 (1.7753 to 4.6356)
SecondarySafety

Summary of Treatment-Emergent Events in Safety Population (participants with at least one dose of study drug). Events assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3: Following is the scale: Grade 1=Mild Adverse Event (AE), Grade 2=Moderate AE, Grade 3=Severe and Undesirable AE, Grade 4=Life-threatening or Disabling AE, and Grade 5=Death Related to AE.)

Time frame:
Up to 24 months
Reported as:
Number · Participants
Safety
ParticipantsSingle Agent Lenalidomide
At least 1 adverse event (AE)53
At least 1 AE related to drug40
At least 1 NCI CTCAE Grade 3-4 AE34
At least 1 NCI CTCAE Gr 3-4 AE related to drug19
At least 1 serious adverse event (SAE)29
At least 1 SAE related to drug16
At least 1 AE leading to drug withdrawal (WD)21
At least 1 AE leading to drug interruption/WD19

Adverse events

Collected over Up to 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Agent Lenalidomide—29/54 (53.7%)53/54 (98.1%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventSingle Agent Lenalidomide
DyspnoeaRespiratory, thoracic and mediastinal disorders4/54
NeutropeniaBlood and lymphatic system disorders3/54
ThrombocytopeniaBlood and lymphatic system disorders3/54
General Physical Health DeteriorationGeneral disorders3/54
PneumoniaInfections and infestations3/54
AnaemiaBlood and lymphatic system disorders2/54
Febrile neutropeniaBlood and lymphatic system disorders2/54
AstheniaGeneral disorders2/54
PyrexiaGeneral disorders2/54
SepsisInfections and infestations2/54
Most frequent other events
Showing 10 of 32
Most frequent other events
EventSingle Agent Lenalidomide
PyrexiaGeneral disorders14/54
ConstipationGastrointestinal disorders12/54
AstheniaGeneral disorders11/54
ThrombocytopeniaBlood and lymphatic system disorders10/54
NeutropeniaBlood and lymphatic system disorders9/54
DiarrhoeaGastrointestinal disorders8/54
Oedema PeripheralGeneral disorders8/54
AnaemiaBlood and lymphatic system disorders7/54
NauseaGastrointestinal disorders7/54
DysphagiaGastrointestinal disorders6/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)Single Agent Lenalidomide
Mean63.2 ± 11.25
Age, Customized
Age, Customized(participants)Single Agent Lenalidomide
<=18 years0
>18 years and < = 65 years28
>65 years26
Sex: Female, Male
Sex: Female, Male(Participants)Single Agent Lenalidomide
Female18
Male36
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Single Agent Lenalidomide
American Indian or Alaska Native0
Asian/Pacific Islander3
Black4
Hispanic1
White45
Other1
Missing0
Region of Enrollment
Region of Enrollment(participants)Single Agent Lenalidomide
France40
United States3
Belgium3
Australia8
Non-Hodgkin's Lymphoma Diagnosis/Histopathology
Non-Hodgkin's Lymphoma Diagnosis/Histopathology(Participants)Single Agent Lenalidomide
Anaplastic large cell lymphoma, primary cutaneous1
Anaplastic large cell lymphoma, primary systemic3
Angioimmunoblastic T-cell lymphoma26
Cutaneous T-cell lymphoma, mycosis fungoides var.3
Extranodal NK T-cell lymphoma, nasal type1
Peripheral T-cell lymphoma, not otherwise charac20
08

Study locations

45 sites
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211-1850, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • The Canberra Hospital Building 3, L 2
    Garran, Australian Capital Territory 2605, Australia
  • Cancer Therapy Centre
    Liverpool, New South Wales 2170, Australia
  • Clinical Research Unit Cairns Base Hospital
    Cairns, Queensland 4870, Australia
  • The Townsville Hospital
    Douglas, Queensland 4814, Australia
  • Royal Brisbane & Women's Hospital
    Herston, Queensland 4029, Australia
  • Ashford Cancer Centre
    Ashford, South Australia 5035, Australia
  • Royal Adelaide Hospital L3 East Wing
    North Terrace, South Australia 5000, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • Box Hill Hospital, 4th Floor, Clive Ward Centre
    Box Hill, Victoria 3128, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Peter MacCallum Cancer Centre
    East Melbourne, Victoria 3002, Australia
  • St Vincents Hospital
    Fitzroy, Victoria 3065, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Institute Jules Bordet
    Bruxelles, 1000, Belgium
  • Cliniques Universitaires St Luc
    Bruxelles, 1200, Belgium
  • KUL
    Leuven, 3000, Belgium
  • Clinique St Pierre
    Ottignies, 1340, Belgium
  • Cliniques universitaires UCL de Mont-Godinne
    Yvoir, 5530, Belgium
  • CHU Hôtel Dieu
    Nantes, Cedex 01 44093, France
  • Hôpital Bretonneau
    Tours, Cédex 1 37044, France
  • CHU Hôpital Hôtel Dieu
    Angers, Cédex 9 49033, France
  • Hôpital Claude Huriez
    Place De Verdun Cedex, Lille 59037, France
  • Hôpital Lapeyronie
    Cedex, Montpellier 34295, France
  • Centre Hospitalier Lyon Sud
    Lyon Sud, Pierre-Bénite 69495, France
  • CHRU Hôpitaux de Brabois - Hématologie
    Vandoeuvre Les Nancy, Rue Morvan Cedex 54511, France
  • Polyclinique Bordeaux Nord Aquitaine
    Bordeaux, 33000, France
  • Hôtel Dieu Pavillon Villemur Pasteur
    Clermont-Ferrand, 63000, France
  • Hopital Henri Mondor
    Creteil, 94010, France
  • CHU de Dijon
    Dijon, 21000, France
  • Hopital Michallon
    Grenoble, 38043, France
  • CHD Les Oudairies
    La Roche Sur Yon, 85000, France
  • CHU Dupuytren
    Limoges, 87042, France
  • Hôpital N.D.de Bon Secours
    Metz, 57000, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • Hôpital Necker
    Paris, 75015, France
  • Hôpital de la Pitié Salpétriere
    Paris, 75651, France
  • CHU Rennes Hôpital Pontchaillou
    Rennes, 35033, France
  • Centre Henri Becquerel
    Rouen, 76038, France
  • Centre René Huguenin
    Saint Cloud, 92210, France
  • Hôpital Purpan
    Toulouse, 31059, France
  • Centre Hospitalier
    Valence, 26953, France
09

References and documents

Publications

  • Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013 Sep;49(13):2869-76. doi: 10.1016/j.ejca.2013.04.029. Epub 2013 May 31. PubMed 23731832 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2008 to primary completion in Mar 2010, 24 months.

Results were first posted in Jan 2012, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2008
First posted
Apr 10, 2008
StartActual
Mar 1, 2008
Primary completionActual
Mar 1, 2010
CompletionActual
Apr 1, 2010
Results first posted
Jan 5, 2012
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00655668
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 10, 2008
Start date
Mar 1, 2008
Primary completion
Mar 1, 2010
Completion
Apr 1, 2010
Results posted
Jan 5, 2012
Last update
Nov 25, 2019

Study contacts

Kenichi Takeshita, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion